Haokun Zhang
Shanghai, 201109, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 29, 2024
Lentiviral vectors for gene therapy of α-thalassemia.
Journal: Science China. Life sciences
Published: October 08, 2024
Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia.
Journal: Journal of genetics and genomics = Yi chuan xue bao
Published: August 04, 2024
Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 15, 2024
In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery.
Journal: Nature biomedical engineering
Published: April 29, 2024
Recalled age of myopia onset may predict risk of high adult myopia in Chinese adults.
Journal: Ophthalmic research
Published: October 14, 2023
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing.
Journal: International journal of molecular sciences
Published: May 07, 2022
Prime Editor 3 Mediated Beta-Thalassemia Mutations of the HBB Gene in Human Erythroid Progenitor Cells.
Journal: International journal of molecular sciences
Published: March 23, 2022
Multi-Omics Analysis in β-Thalassemia Using an HBB Gene-Knockout Human Erythroid Progenitor Cell Model.
Journal: International journal of molecular sciences
Published: December 09, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026